Adamas Pharmaceuticals Inc (NASDAQ:ADMS) CAO Christopher B. Prentiss sold 567 shares of the stock in a transaction that occurred on Wednesday, March 21st. The shares were sold at an average price of $25.98, for a total transaction of $14,730.66. Following the sale, the chief accounting officer now directly owns 17,758 shares in the company, valued at $461,352.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Adamas Pharmaceuticals Inc (NASDAQ ADMS) traded down $0.32 during trading hours on Friday, hitting $24.14. 378,245 shares of the company were exchanged, compared to its average volume of 1,089,281. Adamas Pharmaceuticals Inc has a fifty-two week low of $13.50 and a fifty-two week high of $44.00. The company has a current ratio of 10.79, a quick ratio of 10.69 and a debt-to-equity ratio of 1.55. The firm has a market capitalization of $691.63, a price-to-earnings ratio of -6.06 and a beta of 1.59.

How to Become a New Pot Stock Millionaire

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). The company had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.84 million. During the same quarter last year, the firm posted ($0.68) EPS. The firm’s revenue for the quarter was up 1435.1% compared to the same quarter last year. equities analysts predict that Adamas Pharmaceuticals Inc will post -6.03 earnings per share for the current year.

Hedge funds have recently modified their holdings of the business. Lazard Asset Management LLC acquired a new stake in Adamas Pharmaceuticals in the 4th quarter valued at $1,129,000. JPMorgan Chase & Co. raised its position in shares of Adamas Pharmaceuticals by 13,028.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after buying an additional 135,235 shares in the last quarter. American Century Companies Inc. acquired a new position in Adamas Pharmaceuticals during the 4th quarter worth approximately $2,110,000. Prosight Management LP acquired a new position in Adamas Pharmaceuticals during the 4th quarter worth approximately $407,000. Finally, Deltec Asset Management LLC acquired a new position in Adamas Pharmaceuticals in the 4th quarter valued at approximately $3,399,000. Hedge funds and other institutional investors own 77.25% of the company’s stock.

A number of brokerages have issued reports on ADMS. Northland Securities began coverage on shares of Adamas Pharmaceuticals in a research note on Wednesday, November 29th. They issued an “outperform” rating on the stock. ValuEngine raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Cowen set a $55.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 13th. BidaskClub raised shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 25th. Finally, Needham & Company LLC set a $40.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, February 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. Adamas Pharmaceuticals has an average rating of “Buy” and an average price target of $45.14.

TRADEMARK VIOLATION NOTICE: “Adamas Pharmaceuticals Inc (ADMS) CAO Christopher B. Prentiss Sells 567 Shares” was reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.watchlistnews.com/adamas-pharmaceuticals-inc-adms-cao-christopher-b-prentiss-sells-567-shares/1961310.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.